CM, often mistaken for other heart conditions, where earlier diagnosis and treatment may help improve outcomes 1 PALO ALTO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: ...
As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...
Good afternoon, everyone, and thank you for joining BridgeBio Pharma's Second Quarter 2025 Earnings Call. With me today are Neil Kumar, our CEO; Matt Outten, our Chief Commercial Officer; and Tom ...
Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, ...
BridgeBio Pharma has secured a $300 million upfront payment through a royalty financing agreement with HealthCare Royalty and Blue Owl Capital, which will bolster its financial position and support ...
BridgeBio's Attruby launch crushed expectations, with Q1 revenue triple analyst estimates, driven by higher-than-expected conversion rates and minimal free trial usage. Competitive threats from ...
Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have ...
(RTTNews) - BridgeBio Pharma, Inc. (BBIO), a commercial-stage company, reported narrower net loss for the fourth-quarter, while revenue surged from the prior year on improved product revenue. For the ...
- $36.7 million in first full quarter of U.S. Attruby™ net product revenue and as of April 25, 2025, 2,072 unique patient prescriptions written by 756 unique prescribers - Observational run-in study ...
BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the stocks with explosive growth potential. On February 24, BridgeBio Pharma reported a transformative full-year 2025, marked by a surge in total revenue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results